Sonoma Pharmaceuticals, Inc. — FY2017 Form 10-K
Reporting period: Fiscal year ended March 31, 2017, compared with FY2016. The filing is an annual report; it does not provide a clear standalone FY2017 fourth-quarter financial summary. Amounts below are U.S. dollars.
Business context
Sonoma, formerly Oculus Innovative Sciences, develops and sells dermatology and advanced tissue-care products, including Microcyn-based products, and operates a laboratory testing business. During the year, it changed its name, launched four products, expanded its U.S. dermatology business, and sold certain Latin American assets as it shifted focus toward dermatology.
Financial performance and liquidity
| Metric | FY2017 | FY2016 |
|---|---|---|
| Continuing-operations revenue | $12.825 million | $9.369 million |
| Gross profit / gross margin | $5.668 million / 44% | $2.648 million / 28% |
| Operating expenses | $18.642 million | $17.362 million |
| Loss from continuing operations | $8.669 million | $14.724 million |
| Income from discontinued operations, net of tax | $17.943 million | $4.562 million |
| Net income (loss) | $9.274 million | $(10.162) million |
| Net cash used in operating activities | $8.167 million | $8.746 million |
| Cash and cash equivalents, year-end | $17.461 million | $7.469 million |
| Working capital, year-end | $19.355 million | $9.337 million |
Continuing-operations revenue rose 37%; product revenue rose 48% to $11.957 million. U.S. product revenue increased 51% to $6.580 million, while Europe and rest-of-world product revenue increased 10% to $4.078 million. Service revenue declined to $0.868 million from $1.061 million. Management attributed the higher gross profit partly to the prior-period reclassification of Latin American operations to discontinued operations; the margin comparison is therefore affected by presentation and mix.
FY2017 net income primarily reflects the Latin American asset sale, not profitable continuing operations. The sale generated a reported pretax disposal gain of $19.679 million; discontinued operations contributed $17.943 million after tax. The company continued to use cash in operations despite reporting net income.
Investing activities provided $18.224 million, principally from net sale proceeds of $18.639 million. Financing activities used $0.032 million. Year-end total liabilities were $4.028 million; reported long-term debt was $0.168 million and capital lease obligations were $0.242 million. Contractual obligations totaled $1.123 million, including operating leases. Interest expense was negligible.
Material changes and unusual items
- On October 27, 2016, the company sold specified Latin American intellectual property and territory rights and related assets to Invekra for stated total consideration of $22 million: $18 million at closing, $1.5 million after equipment delivery, and $2.5 million in Mexican-currency installments over ten years tied to services and technical assistance. The latter amount is exposed to currency movements.
- The transaction caused Latin American operations to be presented as discontinued operations for both years. Latin American revenue in discontinued operations was $3.105 million in FY2017 versus $5.715 million in FY2016. The company expects Latin American revenue to fall significantly; it will provide reduced-price product during a transition period of up to two years and expects royalties on certain regional sales.
- The company recorded a $4.268 million income tax benefit in continuing operations and $4.280 million tax expense related to discontinued operations. It maintained a full valuation allowance against deferred tax assets, including substantial tax-loss carryforwards.
- A 1-for-5 reverse stock split took effect in June 2016. The company also adopted a Section 382 rights agreement intended to protect the potential use of tax-loss carryforwards.
Outlook, commentary and risks
Management said cash and cash equivalents were expected to fund working-capital needs and planned sales, marketing and R&D efforts for at least 12 months from the filing date. It also expects continued losses for the foreseeable future and says additional capital may be needed over the longer term. No specific revenue, earnings or margin guidance is provided. Management expects selling, general and administrative costs to rise as it expands its direct U.S. sales force and expects margins to benefit as higher-margin dermatology products grow.
Key risks include the ability to grow U.S. dermatology sales enough to offset lost Latin American business; continuing operating cash burn and possible need for financing; dependence on major customers and distributors; foreign-exchange exposure; product acceptance, reimbursement and pricing pressures; regulatory clearance and compliance; manufacturing continuity; intellectual-property protection; and competition from better-resourced companies. The Petaluma facility has experienced flood risk, and relocation or manufacturing expansion could be costly and require regulatory approvals. The Invekra supply agreement includes a potential penalty of up to $2 million for a prolonged supply failure, which management said it did not expect to incur.
The independent auditor issued an unqualified opinion on the financial statements. Management reported effective disclosure controls and internal control over financial reporting as of March 31, 2017; the auditor was not engaged to audit internal control effectiveness.
Important facts for investors to verify
- How much of the $22 million sale consideration is collected, and the timing, collectability and foreign-currency value of remaining payments and royalties.
- Whether continuing product growth—especially U.S. dermatology growth—can offset reduced Latin American revenue and support improved margins.
- The level and duration of operating cash burn, whether the stated 12-month liquidity outlook remains adequate, and whether additional capital or dilution may be required.
- Customer concentration, receivable collection, and the company’s ability to retain key distributors and meet transition-supply obligations.
- Regulatory, product-liability, reimbursement and manufacturing developments, including facility continuity and the potential costs of expansion or relocation.